Cite
HARVARD Citation
Mok, T. et al. (n.d.). LBA1IMpower133: Primary efficacy and safety + CNS-related adverse events in a phase I/III study of first-line (1L) atezolizumab + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC). Annals of oncology. p. . [Online].